Search Page
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
1983 | 1 |
1984 | 1 |
1987 | 1 |
1988 | 1 |
1989 | 2 |
1992 | 2 |
1994 | 1 |
2000 | 2 |
2001 | 2 |
2002 | 5 |
2003 | 1 |
2004 | 3 |
2005 | 3 |
2006 | 2 |
2007 | 3 |
2008 | 6 |
2009 | 6 |
2010 | 3 |
2011 | 11 |
2012 | 15 |
2013 | 6 |
2014 | 10 |
2015 | 9 |
2016 | 21 |
2017 | 7 |
2018 | 24 |
2019 | 12 |
2020 | 22 |
2021 | 20 |
2022 | 23 |
2023 | 11 |
2024 | 7 |
Search Results
210 results
Results by year
Significantly prolonged OS was reported with tafasitamab plus lenalidomide versus systemic pooled therapies [hazard ratios (HR): 0.55; P = 0.0068], BR (HR: 0.42; P < 0.0001), and R-GemOx (HR: 0.47; P = 0.0003). CONCLUSIONS: RE-MIND2, a retrospective observ
…Absence of p-CREB immunohistochemical expression was significantly associated with 1p/19q codeletion (P < .0001) and identified 1p/19q codeleted tumors, with 70% sensitivity and 100% specificity (area under the curve = 0.85; P < .0001). In addition,
…Absence of p-CREB immunohistochemical expression was significantly associated with 1p/19q codeletion (P < .0001) and identi
…Interim PET remained a strong predictor of PFS (DS 3-5, hazard ratio [HR] 2.4, P = 0.006) in a multivariable analysis and was also an early predictor of both a positive end-of-treatment PET (P < 0.001) and progression of disease within 24 months (POD24) (P
…